Research in Dr. Dinneny's lab is aimed at understanding the response of roots to water-limiting conditions and is exploring this process at different organizational scales from the individual cell type to the level of the whole plant.

Dr. Long's lab uses a multidisciplinary approach to discover new bioactive metabolite pathways and to understand how these pathways control metabolic homeostasis and organismal physiology.

Dr. Sinha is particularly interested in developing and applying novel solutions to alleviate intestinal inflammatory conditions, and on developing more effective therapies and understanding the microenvironment changes in the inflamed versus normal gut in order to identify better therapeutic targets for people with GI immune-­mediated disorders.

Dr. Hiesinger's research interests include investigating the application of molecular and tissue engineering to the translation of angiogenic cytokine therapy for ischemic heart failure and bioengineered devices.

Dr. Haroush’s laboratory studies the mechanisms by which highly complex behaviors are mediated at the neuronal level, mainly focusing on the example of dynamic social interactions and the neural circuits that drive them.

Dr. Karakikes's current research focus is the generation of isogenic induced pluripotent stem cells (iPSCs) using genome-editing technologies to unravel the pathogenesis of familial cardiomyopathies.

Dr. Markman’s research interests include the relationship between language and thought; early word learning; categorization and induction; theory of mind and pragmatics; implicit theories and conceptual change.

Understanding the biology of pre-malignant stem cell mutations and how they contribute to the development of cancer and other age-related diseases is the current focus of work in Dr. Jaiswal's lab.

Dr. Druckmann's lab is interested in elucidating the relationship between behavior and the underlying neuronal circuit structure and neural population dynamics.

Dr. Mahajan's laboratory's focus is the development of personalized medicine for eye diseases through translation of our discoveries in proteomics, genomics, and phenomics in humans, mice and tissue culture models.